Sign in
CompletedNo phase

Segmentectomy vs. Pulmonary Lobectomy in Resectable N1 NSCLC: The VESPER Study (VErification of Segmentectomy Versus Pulmonary Lobectomy in Resectable N1 Non-Small Cell Lung Cancer)

Key facts

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
400 people enrolled
Started
1 Dec 2025
Ended
30 Sept 2026
Type of study
Observational
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Diagnosis of NSCLC
  • Signed informed consent
  • R0 or R(1) resection
  • Surgical treatment involving lobectomy, segmentectomy, or multisegmentectomy
  • Clinical stage N0 or N1
  • Pathological stage N1
  • Maximum tumor diameter ≤ 30 mm

Who cannot take part

  • Neoadjuvant therapy
  • Age < 18 years
  • Emergency lobectomies
  • R1 or R2 resections
  • Histological diagnosis of carcinoid tumor
  • Pathological stage N0 or N2
  • Bilobectomy, pneumonectomy, or extensive resections

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The VESPER study is an international, multicenter, retrospective cohort study designed to compare two surgical approaches-segmentectomy and lobectomy-for patients with non-small cell lung cancer (NSCLC) who have pathologically confirmed N1 lymph node involvement after surgery. The study is sponsor-initiated and non-funded (spontaneous study), led by the Thoracic Surgery Unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Read full original descriptionShow less

Traditionally, lobectomy has been considered the standard surgical treatment for patients with early-stage NSCLC, based on trials showing higher local recurrence rates after more conservative resections such as segmentectomy. However, more recent randomized studies (CALGB 140503 and JCOG0802/WJOG4607L) have shown that, in selected patients with small peripheral tumors (≤2 cm) and no lymph node metastases (clinical N0), sublobar resection-particularly segmentectomy-can achieve similar long-term survival and better preservation of lung function compared with lobectomy, though with a slightly higher local recurrence risk.

Despite these findings, there is still limited scientific evidence regarding the best surgical approach for patients with occult N1 disease (i.e., lymph node metastases discovered only after surgery). Some real-world and database studies suggest that completion lobectomy might not be necessary if a radical segmentectomy with an extended lymph node dissection is performed, but these results have not been validated in a large, multicenter cohort.

The VESPER study aims to fill this evidence gap by analyzing outcomes from nine participating centers. It will include approximately 400 patients who underwent pulmonary resection (segmentectomy, multisegmentectomy, or lobectomy) for pathologic N1 NSCLC between January 2018 and December 2021. About 50 patients are expected to come from the Bologna center.

The primary objective is to compare overall survival (OS) between patients who underwent segmentectomy and those who underwent lobectomy or completion lobectomy. Secondary objectives include evaluating recurrence rates and patterns, disease-free survival (DFS), and perioperative complications (graded by the Clavien-Dindo classification).

The study population includes adults (≥18 years old) with pathologic N1 NSCLC, maximum tumor diameter ≤30 mm, and complete (R0 or R(un)) surgical resection. Patients who had emergency operations, neoadjuvant therapy, carcinoid histology, incomplete resections (R1/R2), or extended pulmonary resections (bilobectomy or pneumonectomy) are excluded.

Data will be collected retrospectively and pseudonymized using the REDCap electronic platform in accordance with Good Clinical Practice (GCP) and European data protection laws. Statistical analyses will use the Kaplan-Meier method for survival estimation, log-rank tests, and Cox proportional hazards models to adjust for potential confounders.

Because of the relatively small sample size of patients undergoing segmentectomy for pN1 disease, the study is exploratory. It is not powered for formal non-inferiority testing but aims to generate valuable real-world data to guide future prospective randomized trials.

No external or commercial funding is involved. Due to privacy restrictions, individual patient data will not be shared publicly. The expected study duration is 10 months (December 2025 - September 2026), including data analysis and dissemination.

Results will be submitted for publication in a peer-reviewed scientific journal within 12 months of study completion, regardless of the outcomes. Abstracts will also be presented at scientific conferences. Authorship will follow contribution guidelines, with the first and last authors affiliated with IRCCS AOU Bologna.

Significance:

The VESPER study will provide new evidence on the safety and long-term outcomes of segmentectomy compared with lobectomy in patients with resectable NSCLC and previously unrecognized N1 disease. By clarifying whether completion lobectomy is necessary after an initially radical segmentectomy, the study seeks to inform more personalized surgical strategies that balance oncologic effectiveness with preservation of lung function and quality of life.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 November 2026